Matrix Metalloproteinases and Coronary Artery Disease: A Novel Therapeutic Target
- 1 November 1997
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 37 (11) , 991-1000
- https://doi.org/10.1002/j.1552-4604.1997.tb04278.x
Abstract
Matrix metalloproteinases (MMP) are a family of enzymes that selectively digest individual components of the extracellular matrix. Their function has been studied in both normal physiologic processes and pathologic states. In the blood vessel, MMPs play an important role in maintaining the vessel's integrity by breaking down extracellular matrix while new matrix is being synthesized. This is necessary to avoid weakening from continuous mechanical stresses. However, in certain environments, these MMPs may contribute to cardiovascular pathologic processes. The purpose of this review is to first discuss the role of MMPs in coronary vascular disease. Evidence suggests that MMPs contribute to the development of de novo atherosclerotic plaques and postangioplasty restenotic plaques by allowing smooth muscle cells to migrate from the vascular media to the intima. Evidence also suggests that MMPs contribute to the rupture of these plaques by degrading the fibrous cap that surrounds them. With this increased molecular information that concerns the pathogenesis of coronary vascular disease, new molecular therapies aimed at altering these processes are being investigated. The rationale, mode of delivery, and prospects for success of these therapies will also be discussed here.Keywords
This publication has 72 references indexed in Scilit:
- Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective de-endothelializationAtherosclerosis, 1996
- Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis.Heart, 1995
- Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.Journal of Clinical Investigation, 1994
- Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque ruptureJournal of the American College of Cardiology, 1994
- Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitroJournal of Cellular Physiology, 1993
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serumFEBS Letters, 1992
- PDGF ligand and receptor gene expression during repair of arterial injury.The Journal of cell biology, 1990
- The biology of platelet-derived growth factorCell, 1986
- Clinical Application of Inhibitors of FibrinolysisDrugs, 1985